Your browser is no longer supported. Please, upgrade your browser.
PAND Pandion Therapeutics, Inc. daily Stock Chart
Pandion Therapeutics, Inc.
Index- P/E- EPS (ttm)- Insider Own4.60% Shs Outstand30.27M Perf Week-3.96%
Market Cap338.12M Forward P/E- EPS next Y-1.65 Insider Trans0.00% Shs Float21.52M Perf Month-22.05%
Income- PEG- EPS next Q-0.41 Inst Own23.70% Short Float1.58% Perf Quarter-37.91%
Sales4.92M P/S68.68 EPS this Y-95.60% Inst Trans- Short Ratio2.14 Perf Half Y-
Book/sh- P/B- EPS next Y24.30% ROA- Target Price- Perf Year-
Cash/sh3.49 P/C3.20 EPS next 5Y- ROE- 52W Range10.52 - 27.75 Perf YTD-38.29%
Dividend- P/FCF- EPS past 5Y- ROI56.50% 52W High-60.00% Beta-
Dividend %- Quick Ratio6.60 Sales past 5Y- Gross Margin- 52W Low5.51% ATR1.21
Employees41 Current Ratio6.60 Sales Q/Q- Oper. Margin- RSI (14)34.62 Volatility11.82% 8.71%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.65 Prev Close11.17
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume158.70K Price11.10
Recom1.70 SMA20-5.53% SMA50-27.83% SMA200-30.54% Volume103,090 Change-0.63%
Aug-11-20Initiated SVB Leerink Outperform $24
Aug-11-20Initiated Morgan Stanley Overweight $25
Aug-11-20Initiated Goldman Buy $28
Aug-10-20Initiated BMO Capital Markets Outperform $29
Oct-20-20 11:57AM  
Sep-24-20 08:00AM  
Sep-10-20 08:00AM  
Aug-31-20 04:05PM  
Aug-23-20 11:33AM  
Aug-16-20 08:59AM  
Aug-07-20 08:15PM  
Jul-17-20 12:03PM  
Jul-16-20 06:20AM  
Pandion Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing various therapeutics to address the unmet needs of patients suffering from autoimmune diseases. Its lead product candidate is PT101, an effector module comprised of an engineered variant of wild-type interleukin-2 (IL-2) fused to a protein backbone that is in Phase 1a clinical trials for the treatment of various autoimmune and inflammatory diseases. The company's other product candidates comprise PT627, a systemic PD-1 agonist that is in preclinical studies for the treatment of autoimmune diseases; PT001, a bifunctional molecule combining its PD-1 agonist effector with a tether module that binds to mucosal vascular addressing cell adhesion molecule (MAdCAM) to drive tissue-selective immunomodulation in the gastrointestinal tract; and PT002, a bifunctional molecule combining its IL-2 mutein effector with a tether module that binds to MAdCAM to drive tissue-selective immunomodulation in the gastrointestinal tract. It has a collaboration with Astellas Pharma Inc. to develop locally acting immunomodulators for autoimmune diseases of the pancreas. The company is headquartered in Watertown, Massachusetts.